Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

Are there any risks of using lacosamide for heart patients?

See the DrugPatentWatch profile for lacosamide

Does Lacosamide Affect Heart Rhythm?

Lacosamide can prolong the PR interval on ECGs, which measures the time for electrical signals to travel from the atria to ventricles. This effect occurs in about 10-40% of patients, depending on dose and population, and is dose-dependent. Clinical trials showed PR prolongation >200 ms in up to 9% of patients on 400 mg/day.[1][2]

What Are the Risks for Patients with Heart Conditions?

Patients with underlying conduction disorders—like second- or third-degree AV block, sick sinus syndrome, or atrial fibrillation without a pacemaker—face higher risks. Lacosamide may worsen bradycardia, AV block, or atrial flutter/fibrillation. It's contraindicated in those with severe cardiac conduction abnormalities. For heart failure patients, caution is advised due to potential negative inotropic effects, though data is limited.[1][3]

How Common Are Cardiac Side Effects?

In pivotal trials (SP756, SP755, SP754), cardiac adverse events were low: bradycardia in 0.3%, AV block in 0.4%, and atrial fibrillation/flutter in 1.1%. Post-marketing reports include rare cases of cardiac arrest or ventricular tachycardia, often in patients with pre-existing heart disease. Risk increases with doses >400 mg/day or concurrent use of drugs that prolong PR interval (e.g., beta-blockers, calcium channel blockers).[1][2]

Can Heart Patients Still Use It Safely?

Yes, with precautions. Baseline ECG is recommended, especially for those with cardiac history. Monitor ECG periodically, avoid if PR >300 ms or QRS >120 ms. Start at low doses (50-100 mg/day) and titrate slowly. Pacemaker presence often allows safe use. Consult cardiology before starting.[1][3]

What Do Guidelines Say?

AAN/AES epilepsy guidelines note cardiac risks but support use in select patients with monitoring. FDA label requires warning for conduction risks; EMA echoes this. No blanket ban for heart patients, but individualized assessment is key.[1][2]

[1]: FDA Lacosamide (Vimpat) Label
[2]: Lacosamide Prescribing Information - European Medicines Agency
[3]: UpToDate: Lacosamide - Adverse Effects



Other Questions About Lacosamide :

Are there any side effects associated with lacosamide dosage? Are there alternative treatments to lacosamide for pregnant women? What medications can lacosamide be combined with? What factors necessitate weekly lacosamide dose changes? What are the most serious side effects of lacosamide? How does lacosamide compare to other antiepileptic drugs? How does lacosamide differ in cost from other treatments?




DrugPatentWatch - Make Better Decisions
© thinkBiotech LLC 2004 - 2026. All rights reserved. Privacy